Rainbow Coral is carving off an ever larger slice of the biosciences pie with each passing day via shrewd partnering with key product and medical technology innovators, as well as via their wholly-owned biotech subsidiary, Rainbow BioSciences, LLC, as the biotech sector alone climbs steadily upwards of some $89.8B in revenues for 2012 (Ernst & Young, Biotech Industry Report 2013).
A leading example of this growth strategy by RBCC occurred in late March this year, as the company moved to form a strategic JV with the developer of an incredible sustained release drug delivery technology for biologics and other sensitive drugs, TheraKine. The TheraKine sustained release delivery platform offers a host of tunable options for extended duration and localized controlled release, whether it’s a six-month linear release or even a quick burst followed by slow release. The drug delivery space is a vital vector for RBCC’s overall strategy and the TheraKine deal is a classic example of how the company is positioning shareholders to profit off the development and commercialization of such highly sought after technologies.
More recently (May 21), RBCC took an even bolder step to capture space in the burgeoning, $142B plus U.S. drug delivery market by opening talks with a potentially key player in the transdermal delivery space working on patch technology. Transdermal patches offer several benefits over typical oral and intravenous methods, ranging from vastly improved bioavailability and longer duration, to greater safety/efficacy (with fewer side effects) and more uniform plasma levels. With estimates on the domestic transdermal delivery space alone upwards of $31.5B in just two year’s time, this deal with a potential leader in the sector could pan out into some serious upside for RBCC investors, especially considering the company’s overall biotech footprint.
One of the company’s most important partners, Nano3D Biosciences (n3D), the developers of an incredibly powerful BioAssembler product line that does 3D cell culture, allowing for researchers to generate extremely lifelike tissues which are nearly identical to those naturally occurring in the body, recently announced (May 13) a major U.S. distribution agreement. One of the big scientific product distributors, MIDSCI out of St. Louis, is intent on pumping out BioAssembler units to the eager domestic cell culture market, which stretches across the life sciences arena from academic and biotech research, to government and pharma.
This distribution deal comes on the heels of last year’s signing of a JV agreement between n3D and Rainbow BioSciences to help develop/market the BioAssembler technology and occurs amid a mounting level of excitement over the far-reaching potential of n3D’s magnetic levitation technology since being featured in the widely-read science journal Nature. When you have the top science journal on the planet calling your technology “the future of cellular research,” that is more than a PR jackpot, it’s something that kicks open the door to unquantifiable opportunities in the sector. There has been a blazing firestorm of coverage since the Nature publication in April’s issue and one look at the technology leaves investors with little to ponder about the potential massive impact of being able to create 3D tissues in the lab.
RBCC is a small company with a solid niche already carved out via its partnerships and the Rainbow BioSciences subsidiary in a much larger field that is dominated by majors like Amgen and Bristol Myers Squibb. With constantly evolving plans in the works, like an upcoming strategic partnership with a Houston-based genomics company that has an amazing 11 NASA-licensed patents that would give RBCC a solid foothold in genetic testing/personalized medicine, the company is growth focused on the global stage with a keen eye on the domestic market.
The global market for just the top 10 drug delivery technologies is headed for around $81.5B by 2015 and RBCC is working with TheraKine to tap that huge capital flow by seeking out new licenses for TheraKine’s portfolio of patented, selective, tunable, and site-specific drug delivery technologies abroad (reported April 24). There are a bounty of overseas healthcare providers just waiting to be harvested by such an advanced sustained-release delivery platform and the addition of new licenses is the best way for RBCC to keep the TheraKine partnership vital.
For more information on Rainbow Coral Corp., visit www.RainbowBiosciences.com
Let us hear your thoughts: Rainbow Coral Corp. Message Board